Progesterone for First Trimester Vaginal Bleeding
Primary Purpose
Threatened Abortion, Pre-Eclampsia, Abruptio Placentae
Status
Withdrawn
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
dihydroxyprogesterone caproate
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Threatened Abortion focused on measuring Threatened Abortion, Progesterone, Subchorionic Hematoma, Pre-Eclampsia, Abruptio Placentae, Fetal Growth Retardation, Premature Birth
Eligibility Criteria
Inclusion Criteria:
- Low risk pregnancies
- Intrauterine pregnancy documented sonographically
- Singleton pregnancy
- Known gestational age
- Healthy women
Exclusion Criteria:
- Women after reproductive assistant techniques
- Women treated with progesterone
- Multiple pregnancies
Sites / Locations
- Soroka University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Progesterone
Placebo
Arm Description
Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
Outcomes
Primary Outcome Measures
adverse pregnancy outcomes
Miscarriage (also gestational age of miscarriage) Sonographic Intrauterine hematoma IUGR Placenta previa Pregnancy induced hypertension and preeclampsia/eclampsia Gestational age at delivery - Preterm delivery (before 37w); Early Preterm delivery (before 34w); and very early (before 28w) Mode of delivery Placental abruption PPROM Induction of labor PPH Apgar score Umbilical cord blood PH at birth Birth weight Fetal malformations Perinatal mortality Admission to the neonatal unit
Secondary Outcome Measures
Uterine artery blood flow velocimetry
Systolic to diastolic ratio, pulsatility index, resistance index and peak systolic velocity
Placental pathological examination
Placental weight and presence of infarcts, calcifications, fibrin deposits or signs of inflammation
Full Information
NCT ID
NCT01501890
First Posted
September 9, 2011
Last Updated
October 24, 2016
Sponsor
Soroka University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT01501890
Brief Title
Progesterone for First Trimester Vaginal Bleeding
Official Title
The Impact of Progesterone Treatment on Obstetrical Outcome Among Women With First Trimester Vaginal Bleeding
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Withdrawn
Why Stopped
never started
Study Start Date
January 2012 (undefined)
Primary Completion Date
December 2013 (Anticipated)
Study Completion Date
September 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Soroka University Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to investigate whether treatment with progesterone for patients with first trimester vaginal bleeding will alter the rates of obstetrical complications and adverse pregnancy outcomes.
Detailed Description
First trimester vaginal bleeding is one of the most common pregnancy complications affecting 15-25% of all pregnancies. Threatened abortion is defined as bleeding through a closed cervical os in the first half of pregnancy. A subchorionic hematoma (SCH) is found in 18-39% of women with a threatened miscarriage and around 70% of women with a SCH will experience vaginal bleeding. Data on the relationship between first trimester vaginal bleeding and obstetric outcome is described mainly in retrospective and noncontrolled studies. It is hypothesized that first trimester bleeding is an indicator of a general tendency for complications (such as: preterm premature rupture of membranes (PPROM), preterm delivery (< 37 weeks gestation; PTD) low birth weight (<1500g; LBW) neonates, small for gestational age (SGA) neonates, placenta previa, placental abruption and stillbirth) later on in pregnancy.
Nowadays, there are not scientific based treatments for the prevention of complications associated with SCH and vaginal bleeding. Nevertheless, recent data have suggested that prophylactic administration of progesterone leads to a significant reduction in the rate of preterm deliveries and SGA neonates among patients with PTD or SGA neonates in the past. Although progesterone administration for threatened miscarriage was not studied, many physicians treat patients with first trimester vaginal bleeding with progesterone. In this era of evidence based medicine, the researchers aim to investigate whether treatment with progesterone for patients with first trimester vaginal bleeding will alter the rates of obstetrical complications and adverse pregnancy outcomes. The researchers hypothesize that treatment with progesterone for first trimester vaginal bleeding will alter the rates of the above mentioned obstetrical complications and adverse pregnancy outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Threatened Abortion, Pre-Eclampsia, Abruptio Placentae, Fetal Growth Retardation, Premature Birth
Keywords
Threatened Abortion, Progesterone, Subchorionic Hematoma, Pre-Eclampsia, Abruptio Placentae, Fetal Growth Retardation, Premature Birth
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Progesterone
Arm Type
Active Comparator
Arm Description
Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
Intervention Type
Drug
Intervention Name(s)
dihydroxyprogesterone caproate
Other Intervention Name(s)
17a-Hydroxyprogesterone caproate
Intervention Description
250mg once a week by intramuscular administration
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Sailine, Physiological water
Intervention Description
0.9% NaCl
Primary Outcome Measure Information:
Title
adverse pregnancy outcomes
Description
Miscarriage (also gestational age of miscarriage) Sonographic Intrauterine hematoma IUGR Placenta previa Pregnancy induced hypertension and preeclampsia/eclampsia Gestational age at delivery - Preterm delivery (before 37w); Early Preterm delivery (before 34w); and very early (before 28w) Mode of delivery Placental abruption PPROM Induction of labor PPH Apgar score Umbilical cord blood PH at birth Birth weight Fetal malformations Perinatal mortality Admission to the neonatal unit
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Uterine artery blood flow velocimetry
Description
Systolic to diastolic ratio, pulsatility index, resistance index and peak systolic velocity
Time Frame
One month after recruitment upon completion of treatment
Title
Placental pathological examination
Description
Placental weight and presence of infarcts, calcifications, fibrin deposits or signs of inflammation
Time Frame
After delivey participants will be followed for the duration of hospital stay, an expected average of 3 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Low risk pregnancies
Intrauterine pregnancy documented sonographically
Singleton pregnancy
Known gestational age
Healthy women
Exclusion Criteria:
Women after reproductive assistant techniques
Women treated with progesterone
Multiple pregnancies
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ralika Hershkovitch, MD
Organizational Affiliation
Soroka University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Soroka University Medical Center
City
Beer Sheva
Country
Israel
12. IPD Sharing Statement
Citations:
PubMed Identifier
20410766
Citation
Lykke JA, Dideriksen KL, Lidegaard O, Langhoff-Roos J. First-trimester vaginal bleeding and complications later in pregnancy. Obstet Gynecol. 2010 May;115(5):935-944. doi: 10.1097/AOG.0b013e3181da8d38.
Results Reference
background
Learn more about this trial
Progesterone for First Trimester Vaginal Bleeding
We'll reach out to this number within 24 hrs